Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 35

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 2
Chunk 35
---
 net cash flow activity for
the six months ended June 30, 2025 and 2024:

    Six Months Ended June 30, 2025  
    Six Months Ended June 30, 2024 
  
    Net cash used in operating activities 
    $(61,436) 
    $(207,444)
  
    Net cash provided by financing activities 
     –  
     55,000 
  
    Net change in cash and cash equivalents 
    $(61,436) 
    $(152,444)

Cash Flows From Operating Activities 

Net cash used in operating activities for the six
months ended June 30, 2025 consisted of our net loss of $353,348, which amount was offset by (i) non-cash interest expense of $36,365
and (ii) a net change in operating assets and liabilities of $255,247, primarily due to an increase in accrued compensation of $244,346.

Net cash used in operating activities for the six
months ended June 30, 2024 consisted of our net loss of $582,209, which amount was offset by (i) non-cash share-based compensation expense
of $4,867, (ii) non-cash interest expense of $37,698, (iii) the accretion to redemption value on convertible notes of $1,446, and (iv)
a net change in operating assets and liabilities of $330,758 primarily due to an increase in accrued compensation of $327,566.

 20 

Cash Flows From Financing Activities

Net cash provided by financing activities for the
six months ended June 30, 2024 consisted of proceeds received from loan payable from Oncotelic totaling $55,000.

Recently Adopted Accounting Standards

There have been no new accounting pronouncements adopted
by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the three and six months ended
June 30, 2025, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K
for the year ended December 31, 2024, that the Company believes are of significance or potential significance to the Company.

    Item 3.
    Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company” as defined
in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by